Tachykinin NK2 receptor antagonists

Handbook of Experimental Pharmacology

Volumn 164, Issue , 2004, Pages 219-244

  Emonds Alt, X ^a  

^a SANOFI   (France)

Author keywords

Antagonist; MENl1420; Nepadutant; Neurokinin A; Saredutant; SR48968; Tachykinin NK2 receptor

Indexed keywords

1 [2 (5 FLUORO 1H INDOL 3 YL)ETHYL] 4 METHOXY [(PHENYLSULFINYL)METHYL]PIPERIDINE; 3 [1 [2 [4 BENZOYL 2 (3,4 DIFLUOROPHENYL) MORPHOLIN 2 YL]ETHYL] 4 PHENYLPIPERIDIN 4 YL] 1 DIMETHYLUREA; 4 [(4 CHLOROPHENYL)AMINO] 5,6 DIHYDRO 2 [4 [2 (HYDROXYIMINO) 1 OXOPROPYL] 1 PIPERAZYINYL] 6 (1 METHYLETHYL) 7H PYRROLO(3,4 D)PYRIMIDIN 7 ONE; BENZOYLALANYLALANYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO PROLYLPROLYLNORLEUCINAMIDE; CYCLIC PSEUDOPEPTIDE; CYCLO(GLUTAMINYLTRYPTOPHYLPHENYLALANYLGLYCYLLEUCYLMETHIONYL); CYCLOHEXYLCARBONYLGLYCYLALANYL DEXTRO TRYPTOPHYLPHENYLALANINE DIMETHYLAMIDE; CYCLOPEPTIDE; GR 112000; GR 83074; MEN 10573; MEN 10612; MEN 10627; MEN 10677; N (1,2,2 TRIMETHYLPROPYL) 3 [(4 PIPERIDIN 1 YL)PIPERIDIN 1 YL]METHYL 2 PHENYLQUINOLINE 4 CARBOXAMIDE; NEPADUTANT; NEUROKININ A [4-10][5 TYROSINE 6,8,9 DEXTRO TRYPTOPHAN 10 ARGININE]; NEUROKININ A [4-10][5 TYROSINE 6,8,9 DEXTRO TRYPTOPHAN 10 LYSINE]; PSEUDOPEPTIDE; SAREDUTANT; TACHYKININ NK2 RECEPTOR; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 84979202596     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-18891-6_7     Document Type: Article

References (151)

1. Abdel-Gawad M, Dion SB, Elhilali MM (2001) Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. J Urol 165: 1739-1744
2. 1 receptor further characterized in the lung with nonpeptide receptor antagonists. Can J Physiol Pharmacol 73: 878-884
3. Advenier C, Emonds-Alt X (1996) Tachykinin receptor antagonists and cough. Pulmon Pharmacol 9: 329-333
4. 1) receptors. Am Rev Respir Dis 146: 1177-1181
5. 2) receptor revisited with SR48968, a potent non-peptide antagonist. Biochem Biophys Res Commun 184: 1418-1424
6. 2 receptor antagonist. Eur J Pharmacol 250: 169-171
7. Aharony D, Buckner CK, Ellis JL, Ghanekar SV, Graham A, Kays JS, Little J, Neeker S, Miller SC, Undem BJ,Waldron IR (1995) Pharmacological characterization of a new class of non-peptide neurokinin A antagonists that demonstrate species selectivity. J Pharmacol Exp Ther 274: 1216-1221
8. Altamura M, Canfarini F, Catalioto RM, Guidi A, Pasqui F, Renzetti AR, Triolo A, Maggi CA (2002) Successful bridging from a peptide to a nonpeptide antagoni st at the human tachykinin NK-2 receptor. Bioorg Med Chern Lett 12: 2945-2948
9. Anton PM, Theodorou V, Fioramonti J, Bueno L (2001) Chronic low-level administration of diquat increases the nociceptive response to gastric distension in rats: role of mast cells and tachykinin receptor activation. Pain 92: 219-227
10. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug anatgon ists. Br J Pharmacol 14: 48-58
11. 2-receptor, GR159897. Br J Pharmacol 112 (Suppl): 48P
12. 2 antagon ist in rat and human. Xenobiotica 30: 627-642
13. 2 antagonist, UK-224,671. Eur J Pharm Sci 12: 41-50
14. 2 receptor mRNAin human brain. Neurosci Lett 303: 25-28
15. 2 receptors.. Eur J Pharmacol. 272: 241-248
16. 2 antagonists. Bioorg Med Chern Lett 11: 2769-2773
17. Bhogal N, Donnelly D, Findlay JB (1994) The ligand binding site of the neurokinin-2 receptor. Site-directed mutagenesis and identification of neurokinin Abind ing residues in the human neurokinin-2 receptor. J Bioi Chern 269: 27269-27274
18. Birder LA, Kiss S, DE Groat WC, Lecci A, Maggi CA (2003) Effect of nepadutant, a neurokinin-2 Tachykinin receptor antagonist, on immediate-early gene expression after trinitrobenzenzsulfonic acid-induced colitis in the rat. J Pharmacol Exp Ther 304: 272-276
19. Blaney FE, Raveglia LF, Artico M, Cavagnera S, Dartois C, Farina C, Grugni M, Gagliardi S, Luttmann MA, Martinelli M, Nadler GMMG, Parini C, Petrillo P, Sarau HM, Scheideler MA, Hay DWP, Giardina GAM (2001) Stepwise modulation of neurokinin3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. J Med Chern 44: 1675-1689
20. 2 receptor antagonist, SR48968, of antigen-induced airway hyperresponsiveness in sensitized guinea pigs. Br J Pharamcol 114: 259-261
21. 2 receptors in subtance P-induced microvascular leakage hypersensitivity and airway hyperesponsiveness in guinea pigs. Eur Respir J 9: 1445-1450
22. Boichot E, Germain N, Emonds-Alt X, Advenier C, Lagente V (1998) Effects of SR140333 and SR48968 on antigen and substance P-induced activation of guinea-pig alveolar macrophages. Clin Exp Allergy 28: 1299-1305
23. 2 receptor antagonists. Bioorg Med Chern 2: 101-113
24. 2 receptors and enhancement of cholinergic transmission in the inflamed rat colon: an in vivo motil ity study. Br J Pharmacol 133: 1107-1113
25. 2 receptor antagonist. Br J Pharmacol 123: 81-91
26. Chardenot P, Roubert C, Galiegue S, Casellas P, Le Fur G, Soubrie P, Oury-Donat F (2002) Expression profile and up-regulation of PRAX-l mRNA by antidepressant treatment in the rat brain. Mol Pharmacol 62: 1314-1320
27. Chopin A, Groke G, Bringas A, Stepan G, Dillon MP (2002) Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology 65: 96-102
28. Chu M, Chan TM, Das P, Mierzwa R, Patel M, Puar MS (2000) Structure of SCH 218157, a cyclodepsipeptide with neurokinin A activ ity. J Antibiot 53: 736-738
29. 2 receptor antagonists. Bioorg Med Chern Lett 4: 1951-1956
30. 2 receptors in rats. J Pharm Pharmacol 46: 383385
31. 2 receptor antagonists, SR140333 and SR48968,in different rat and guinea-pig intestinal segments. Life Sci 56: 267-275
32. Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand JP, Manara L (1997) Role oftachykinin in castor oil diarrhoea in rats. Br J Pharmacol 121: 375-380
33. Croci T, Aureggi G, Manara L, Ernonds-Alt X, Le Fur G, Maffrand JP, Mukenge S, Feria G (1998) In vitro characterizat ion of tachykinin NK-2 receptors modulating motor responses of human colonic muscle strips. Br J Pharmacol 124: 1321-1327
34. 2 receptor antagonist nepadutant in acute recto colitis induced by diluted acetic acid in guinea pigs. Neuropeptides 34: 355-359
35. 2 receptor of CRF] receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea pig. Neuropeptides 37: 89-97
36. Dion S, Rouissi N, Nantel F, Iukic D, Rhaleb NE, Tousignant C, Telemaque S, Drapeau G, Regoli D, Naline E, Advenier C, Rovero P, Maggi CA (1990) Structure-activity study of neurokinins: antagonists for the neurokinin-2 receptor. Pharmacology 41: 184-194
37. 2) receptor. Life Sci 50: PLlOI-PLl06
38. 2) receptor antagonist. Regul Pept 46: 31-36
39. Emonds-Alt X, Doutremepuich JD, Healme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux JP, Proietto V, Van Broeck D, Soubrie P, Le Fur G, Breliere JC (1993b) In vitro and in vivo biological activities of SR 140333, a novel potent nonpeptide tachykinin NK1 receptor antagonis t. Eur J Pharmacol 250: 403-413
40. Emonds-Alt X, Golliot F, Pointeau P, Le Fur G, Breliere JC (1993c) Characterization of the binding sites of [3HlsR 48968, a potent nonpeptide radioligand antagonist of th e neurokinin-2 receptor. Biochem Biophys Res Commun 191: 1172-1177
41. 2) receptor. Bioorg Med Chern Lett 3: 925-930
42. 2 receptor. Drugs of the Future 20: 701-707
43. 3 receptor. Life Sci 56: PL27PL32
44. 2 receptor antagonist. Neuropeptides 31: 449-458
45. 2 receptors in rat colonic hypersecretion induced by interleukin 1f3: role of nitric oxyde. Gastroenterology 109: 483-489
46. Gaultier E, Emonds-Alt X, Fioramonti J, Bueno L (2002) Neurokinin 2 and neurokinin 3 receptor antagonists, SR48968 and SR142801, reduce colonic hypersensitivity induced by inflammation and stress in rats, but do not modify colonic transit time. Gastroenterology 122: A-526
47. Giannotti D, Perrotta E, Di Bugno C, Nannicini R, Harmat JS, Giolitti A, Patacchini R, Renzetti AR, Rotondaro L, Giuliani S, Altamura M, Maggi CA (2000) Discovery of cyelic pseudopeptide human tachykinin NK-2 receptor antagonists. J Med Chern 43: 4041-4044
48. Giolitti A, Altamura M, Bellucci F, Giannotti D, Meini S, Patacchini R, Rotondara L, Zappitelli S, Maggi CA (2002) Monocyelic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyelic antagonist: QSAR and site-directed mutagenesis studies. J Med Chern 45: 3418-3429
49. Girard V, Naline E, Emonds-Alt X, Advenier C (1995) Effect of two tachykinin antagonists, SR48968 and SR140333, on cough induced by citric acid in the unanaesthetized guinea pig. Eur Respir J 8: 1110-1114
50. 2 receptor antagonist SR48968 inhibits citric acid-induced airway hyperresponsiveness in guinea pigs. Am J Respir Crit Care Med 153: 1496-1502
51. 2 receptor antagonists in the human isolated urinary bladder. J Auton Pharmacol 16: 251-259
52. 2 receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs. Eur J Pharmacol 415: 61-71
53. Griebel G, Moindrot N, Alaiga C, Simiand J, Soubrie P (2001a) Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci Biobehav Rev 25: 619-626
54. 2 receptor antagonist on emotional processes in rodents. Psychopharmacology 158: 241-251
55. 2 receptor antagonists. Regul Pept 46: 9-19
56. Harbeson SL, Rovero P (1994) Structure-activity relationships of agonist and antagonist ligands. In: Buck SH (ed) The tachykinin receptor. Humana Press, Totowa, New Jersey, pp 329-365
57. Harmat NJS, Giannotti D, Nannicini R, Perrotta E, Criscuoli M, Patacchini R, Renzetti AR, Giuliani S, Altamura M, Maggi CA (2002) Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclo-pseudopeptides: new antagonists for the human tachykinin NK-2 receptor. Bioorg Med Chern Lett 12: 693-696
58. Hay DWP, Giardina GAM, Griswold DE, Underwood DC, Kotzer Cl, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Martin LD, Kilian D, Legos JJ, Barone FC, Luttmann MA, Grugni M, Raveglia LF, Sarau HM (2002) Nonpeptide tachykinin receptor antagonist. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. J Pharmacol Exp Ther 300: 314-323
59. 2) antagonists: fermentation, isolation, physico-chemical properties, and biological activities. J Antibiot 54: 125-135
60. 2 receptor antagonist TAC-363. Yakugaku Zasshi 116: 884-891
61. 2 receptor antagonist, TAC-363, on bronchoconstriction and airway hyperresponsiveness in guinea pigs. Nippon Yakurigaku Zasshi 109: 19-29
62. Holzer P, Holzer-Petsche U (1997a) Tachykinins in the gut. Part I. Expression, relaese and motor function. Pharmacol Ther 73: 173-217
63. Holzer P, Holzer-Petsche U (1997b) Tachykinins in the gut. Part II. Role in neural excitation, secretion and inflammation. Pharmacol Ther 73: 219-263
64. 2 receptor antagonist, on animal model of asthma. Abstracts of the 74th Annual Meeting of the Japanese Pharmacological Society P-551
65. 2) receptor. Bioorg Med Chern Lett 5: 2879-2884
66. 2) receptor. Bioorg Med Chern Lett 8: 1935-1940
67. Ioos GF, Pauwels RA (2001) Tachykinin receptor antagonists: potential in airways diseases. Curr Opin Pharmacol 1: 235-241
68. Julia V, Bueno L (1997) Tachykinergic mediation of viscerosensitive responses to acute inflammation in rats: role ofCGRP. Am J Physiol 272: G141-G146
69. Julia V, Morteau O., Bueno L (1994) Involvement of neurokinin a nad neurokinin 2 receptors in vicerosensitive response to rectal distension in rats. Gastroenterology 107: 94102
70. Kenakin T (1993) Pharmacologic analysis of drug-receptor interaction. 2nd edn. Raven Press, New York
71. Kraan J, Vink-Klooster H, Potsrna DS (2001) The NK-2 receptor anatgonist SR48968C does not improve adenosine hyperresponsiveness and airawy obstruction in allergic asthma. Clin Exp Allergy 31: 274-278
72. Kubota H, Fujii M, Ikeda K, Takeuchi M, Shibanuma T, Isomura Y (1998a) Spiro-substituted piperidines as neurokinin receptor antagonists. I. Design and synthesis of (+/-)-N- [2-(3,4-dichlorophenyl)-4-(spiro[isobenzofuran-I (3H),4‘piperidin] -1'-yl)butyl]-N-methylbenzamide, YM-35375, as a new lead compound for novel neurokinin receptor antagonists. Chern Pharm Bull 46: 351-354
73. 1 receptor-antagonistic activities of N-[2-aryl -4-(spiro-substituted piperidin-I’-yl)butyl]carboxamides. Chern Pharm Bull 46: 242-254
74. 1 receptors. Neuropharmacology 40: 696-701
75. 1 receptor antagonist, reduces motor responses induced by the intravesical administration of capsaicin in vivo. Naunyn-Schmiedeberg’s Arch Pharmacol 356: 182-188
76. 1 receptors on colonic motility in anesthetized rats: effects of agonists. Can J Physiol Pharmacol 74: 582-586
77. Lecci A, Giuliani S, Tramontana M, Santicioli P, Criscuoli M, Dion S, Maggi CA (1998a) Bladder distension and activation of the efferent function of sensory fibres: similarities with the effect of capsaicin. Br J Pharmacol 124: 259-266
78. 1 receptor blockade on detrusor hyperreflexia induced by bacterial toxin in rats. J Urol 160: 206-209
79. Lecci A, Carini F,Tramontana M, Birder LA, de Groat WC, Saznticioli P, Giuliani S, Maggi CA (2001a) Urodynamic effects induced by intravesical capsaicin in rats and hamsters. Auton Neurosci 91: 37-46
80. Lecci A, Carini F, Tramontana M, D’Aranno V, Marinoni E, Crea A, Bueno L, Fioramonti J, Criscuoli M, Giuliani S, Maggi CA (2001b) Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK1 receptor antagonist are altered by intestinal inflammation in rodent models. J Pharmacol Exp Ther 299: 247-254
81. 1 receptor anatgonist MEN 11420 (NEPADUTANT) in rats. Drug Metab Dispos 26: 1077-1081
82. Lombardi A, D’Agostino B, Filippelli A, Pedone C, Matera MG, Falciani M, De Rosa M, Rossi F, Pavone V (1998a) Neuronorm is apotent and water soluble neurokinin A receptor antagonist. Bioorg Med Chern Lett 8: 1735-1740
83. Lombardi A, D’Agostino B, Nastri F, D’Andrea LD, Filippelli A, Falciani M, Rossi F, Pavone V (1998b) A novel super-potent neurokinin A receptor antagonist conta ining dehydroalanine. Bioorg Med Chern Lett 8: 1153-1156
84. 1 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 134: 215-223
85. MacKenzie AR, Marchington AP, Middleton DS, Newman SD, Jones BC (2002) Structureactivity relationships of l-alkyl-5-(3,4-dichlorophenyl)-5-[2-[(substitutedj-I-azetidinyl] ethyl]-2-piperidones. 1. Selective antagonists of neurokinin-2 receptor. J Med Chern 45: 5365-5377
86. Maggi CA (1995) Tachykinin receptors. In: Ruffolo RR, Hollinger MA (eds) G-protein coupled transmembrane signaling mechanisms. CRC Press, Boca Raton, Ann Arbor, London, Tokyo, pp 95-151
87. Maggi CA, Giuliani S, Ballati L, Lecci A, Manzini S, Patacchini R, Renzetti AR, Rovero P, Quartara L, Giachetti A (1991) In vivo evidence for tachykinergic transmission using a new NK-2 receptor selective antagonist, MEN 10,376. J Pharmacol Exp Ther 257: 1172-1178
88. 2 receptors in preparation from different species. Neuropeptides 22: 93-98
89. Maggi CA, Patacchini R, Rovero P, Giachetti A (1993a) Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 13: 23-93
90. Maggi CA, Quartara L, Patacchini R, Giuliani S, Barbanti G, Turini D, Giachetti A (1993b) MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are potent tachykinin NK-2 receptor antagonists. Regul Pept 47: 151-158
91. 2 receptor antagonist. Eur J Pharmacol 234: 83-90
92. 2 receptors. J Pharmacol Exp Ther 271: 14891500
93. Martin CAE, Naline E, Emonds-Alt X, Advenier C (1992) Influence of (±) -CP-96,345 and SR48968on electrical field stimulation of the isolated guinea-pig main bronchus. Eur J Pharmacol 224: 137-143
94. Martin CAE, Emonds-Alt X, Advenier C (1993) Inhibition of cholinergic neurotransmission in isolated guinea-pig main bronchi by SR48968. Eur J Pharmacol 243: 309-312
95. 2 receptor. Abstracts of the 74th Annual Meeting of the Japanese Pharmacological Society. P-561
96. Mayer EA, Collins SM (2002) Evolving pathophysiologic models of functional gastrointestinal disordres. Gastroenterology 122: 2032-2048
97. Mazelin L, Theodorou V, More J, Emonds-Alt X, Fioramonti J, Bueno L (1998) Comparative effects of nonpeptide tachykinin receptor antagonists on experimental gut inflammation in rats and guinea pigs. Life Sci 63: 293-304
98. McElroy AB, Clegg SP, Deal MJ, Ewan GB, Hagan RM, Ireland SJ, Jordan CC, Porter B, Ross BC, Ward P, Whittington AR (1992) Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor. J Med Chern 35: 2582-2591
99. McKnight AT, Maguire JJ, Williams BJ, Foster AC, Tridgett R, Iversen LL (1988) Pharmacological specificity of synthetic peptides as antagonists at tachykinin receptors. Regul Pept 22: 127
100. McKnight AT, Maguire JJ, Elliott NJ, Fletcher AE, Foster AC, Tridgett R, Williams BI, Longmore I, Iversen LL (1991) Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors. Br J Pharmacol 104: 355-360
101. 2 receptors. Eur J Pharmacol 337: 279-282
102. Middleton D (2002) Balancing potency and oral bioavailability. The design and profile of neurokinin-2 antagonists for the treatment of urinary urge incontinence. Abstracts of the 223rd National Meeting of the American Chemical Society MEDI-137
103. Patacchini R, Maggi CA (1995) Tachykinin receptors and receptor subtypes. Arch Int Pharmacodyn 329: 161-184
104. Patacchini R, Maggi CA (2001) Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 429: 13-21
105. Patacchini R, Quartara L, Rovero P, Goso C, Maggi CA (1993) Role of C-term inal amidation on the biological activity of neurokinin A derivatives with agonist and antagonist properties. J Pharmacol Exp Ther 264: 17-21
106. Patatacchini R, Bartho L, Maggi Ca (1997a) Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct. Br J Pharmacol 122: 1633-1638
107. 2 receptor antagonists in the human isolated ileum and colon. Neuropeptides 31: 71-77
108. Patacchini R, De Giorgio R, Bartho L, Barbara G, Corinaldesi R, Maggi CA (1998a) Evidence that tachykinins are the main NANC excitatory neurotransmitters in the guinea-pig common bile duct. Br J Pharmacol 124: 1703-1711
109. Patacchini R, Santicioli P, Zagorodnyuk V, Lazzeri M, Turini D, Maggi CA (1998b) Excitatory motor and electrical effects produced by tachykinins in the human and guinea pig isolated ureter and guinea-pig renal pelvis. Br J Pharmacol 125: 987-996
110. 2 receptor mediates contraction and ion transport in rat colon by different mechanisms. Eur J Pharmacol 415: 277-283
111. Pavone V, Lombardi A, Maggi CA, Quartara L, Pedone C (1995a) Conformational rigid ity versus flexibility in a novel peptidic neurokinin A receptor antagonist. J Pept Sci 1: 236-240
112. Pavone V, Lombardi A, Nastri F, Saviano M, Maglio O, D’Auria G, Quartara L, Maggi CA, Pedone C (1995b) Design and structure of a novel neurokinin A receptor anatgonist cyclotM et-Asp -Trp-Phe-Dap-Leulcyclofzji-Sji). Perkin Trans 2: 987-993
113. 2 receptor antagonist, in guinea -pig airways. Eur J Pharmacol 273: 129-135
114. 2 receptors in a spinal nociceptive reflex in the rat. Eur J Pharmacol 232: 255-261
115. Poncelet M, Gueudet C, Emonds-Alt X, Breliere JC, Le Fur G, Soubrie P (1993) Turning behavior induced in mice by a neurokinin A receptor agonist: stereoselective blockade by SR48968,a non-peptide receptor antagonist. Neursci Lett 149: 40-42
116. Qian Y, Emonds-Alt X, Advenier C (1993) Effects of capsaicin, (±) -CP-96,345 and SR48968 on the bradykinin-induced airways microvascular leakage in guinea pigs. Pulm Pharmacol 6: 63-67
117. Quartara L, Fabbri G, Ricci R, Patacchini R, Pestellini V, Maggi CA, Pavone V, Giachetti A, Arcamone F (1994) Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists. J Med Chern 37: 3630-3638
118. 2 receptor antagonist s. Med Res Rev 15: 139-155
119. 2 antagonist MEN 10627. Regul Pept 65: 55-59
120. Regoli D, Boudon A, Fauchere JL (1994) Receptors and ant agonist s for substance P and related peptides. Pharmacol Rev 46: 551-599
121. 2 receptor. Biochem Biophys Res Commun 248: 78-82
122. 2-receptor mediated contraction in monkey, guinea -pig and human aiway smooth muscle. Neuropeptides 33: 27- 34
123. Rovero P, Pestellini V, Maggi CA, Patacchini R, Regoli D, Giachetti A (1990) A highly potent NK-2 tachykinin receptor antagonist containing D-tr yptophan. Eur J Pharmacol 175: 113-115
124. 2B receptor subtype. Neuropeptides 23: 143-145
125. 2 binding sites in the rat brain. J Neurochem 79: 985-996
126. 2 receptor antagonist in the guinea-pig and human colon. Naunyn -Schmiedeberg’s Arch Pharmacol 356: 678-688
127. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GAM, Hay DWP (1997) Nonpeptide tachykinin receptor antagonist. I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 281: 1303-1311
128. Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GAM, Hay DWP (2000) Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther 295: 373-381
129. Selway CN, Terrett NK (1996) Parallel-compound synthesis: methodology for accelerating drug discovery. Bioorg Med Chern 4: 645-654
130. 2 receptors. Neuropeptides 29: 281-292
131. 2 antagonists Bioorg Med Chern Lett 3: 931-936
132. 2 receptor antagonists. J Med Chern 38: 3772-3779
133. Steinberg R, Rodier D, Souilhac J, Bougault I, Emonds-Alt X, Soubrie P, Le Fur G (1995) Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum. An in vivo microdyalysis study. J Neurochem 65: 2543-2548
134. Steinberg R, Marco N, Voutsinos B, Bensaid M, Rodier D, Souilhac J, Alonso R, Oury-Donat F, Le Fur G, Soubrie P (1998a) Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat. Eur J Neurosci 10: 2337-2345
135. Steinberg R, Souilhac J, Rodier D, Alonso R, Emonds-Alt X, Le Fur G, Soubrie P (1998b) Facilitation of striatal acetylcholine release by dopamine D1 receptor stimulation: involvement of enhanced nitric oxide production via neurokinin-2 receptor activation. Neuroscience 84: 511-518
136. Steinberg R, Alonso R, Griebel G, Bert L, Lung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrie P (2001) Selective blockade of neurokinin-2 receptor produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299: 449-458
137. 2 receptor antagonists in mouse light-dark box. Eur J Pharmacol 250: Rll-R12
138. Teixeira RM, Santos ARS, Ribeiro SJ, Calixto JB, Rae GA, De Lima TCM (1996) Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311: 7-14
139. 2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 129: 193-199
140. 2 receptors in gastric barosensitivity and in experimental ileus in rats. Neurogastroenterol Motil 13: 45-53
141. 2 receptor antagonist, in guinea pigs. Eur J Pharmacol 352: 279-288
142. 2 receptors in the hamster urinary bladder: in vitro and in vivo characterization. Naunyn-Schmiedeberg’s Arch Pharmacol 358: 293-300
143. Tramontana M, Santicioli P, Giuliani S, Catalioto RM, Lecci A, Carini F, Maggi CA (2002) Role of tachykinins in sephadex-indiced airway hyperreactivity and inflammation in guinea pigs. Eur J Pharmacol 439: 149-158
144. 2 tachykinin receptor antagonist SR48968 (saredutant) on beurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 12: 17-23
145. 2) receptor. Neuropeptides 24(Suppl): 236
146. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 121: 186-191
147. Williams BJ, Curtis NR, McKnight AT, Maguire J, Foster A, Tridgett R (1988) Development ofNK-2 selective antagonists. Regul Pept 22: 189
148. Williams BJ, Curtis NR, McKnight AT, Maguire JJ, Young SC, Veber DF, Baker R (1993) Cyclic peptides as selective tachykinin antagonists. J Med Chern 36: 2-10
149. 2 antagonists. Int J Peptide Protein Res 41: 376-384
150. Yashpal K, Dam TV, Quirion R (1990) Quantitative auto radiographic distribution of multiple neurokinin binding sites in rat spinal bordo Brain Res 506: 259-266
151. Yashpal K, Hui-Chan CW, Henry JL (1996) SR48968 specifically depresses neurokinin A-vs. substance P-induced hyperalgesia in a nociceptive withdrawal reflex. Eur J Pharmacol 308: 41-48